| Year |
Citation |
Score |
| 2024 |
Venkatasubramanian M, Schwartz L, Ramachandra N, Bennett J, Subramanian KR, Chen X, Gordon-Mitchell S, Fromowitz A, Pradhan K, Shechter D, Sahu S, Heiser D, Scherle P, Chetal K, Kulkarni A, ... ... Starczynowski DT, et al. Broad de-regulated U2AF1 splicing is prognostic and augments leukemic transformation via protein arginine methyltransferase activation. Biorxiv : the Preprint Server For Biology. PMID 38370617 DOI: 10.1101/2024.02.04.578798 |
0.335 |
|
| 2023 |
Marion W, Koppe T, Chen CC, Wang D, Frenis K, Fierstein S, Sensharma P, Aumais O, Peters M, Ruiz-Torres S, Chihanga T, Boettcher S, Shimamura A, Bauer DE, Schlaeger T, ... ... Starczynowski D, et al. RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia. Leukemia. PMID 37391485 DOI: 10.1038/s41375-023-01945-6 |
0.338 |
|
| 2023 |
Dean ST, Ishikawa C, Zhu X, Walulik S, Nixon T, Jordan JK, Henderson S, Wyder M, Salomonis N, Wunderlich M, Greis KD, Starczynowski DT, Volk AG. Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development. Blood Advances. PMID 37205848 DOI: 10.1182/bloodadvances.2022009438 |
0.318 |
|
| 2023 |
Bennett JR, Ishikawa C, Agarwal P, Yeung J, Sampson A, Uible E, Vick E, Bolanos L, Hueneman KM, Wunderlich M, Kolt A, Choi K, Volk AG, Greis KD, Rosenbaum JS, ... ... Starczynowski DT, et al. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML. Blood. PMID 37172199 DOI: 10.1182/blood.2022018718 |
0.311 |
|
| 2022 |
Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, ... ... Starczynowski DT, et al. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine. 14: eabb7695. PMID 35263148 DOI: 10.1126/scitranslmed.abb7695 |
0.301 |
|
| 2022 |
Muto T, Guillamot M, Yeung J, Fang J, Bennett J, Nadorp B, Lasry A, Redondo LZ, Choi K, Gong Y, Walker CS, Hueneman K, Bolanos LC, Barreyro L, Lee LH, ... ... Starczynowski DT, et al. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. PMID 35045331 DOI: 10.1016/j.stem.2021.12.007 |
0.342 |
|
| 2021 |
Niederkorn M, Ishikawa C, M Hueneman K, Bartram J, Stepanchick E, R Bennett J, E Culver-Cochran A, Bolanos LC, Uible E, Choi K, Wunderlich M, Perentesis JP, M Chlon T, Filippi MD, Starczynowski DT. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia. PMID 34465865 DOI: 10.1038/s41375-021-01394-z |
0.337 |
|
| 2020 |
Schieber M, Marinaccio C, Bolanos LC, Haffey WD, Greis KD, Starczynowski DT, Crispino JD. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. Blood Cancer Journal. 10: 98. PMID 33024076 DOI: 10.1038/s41408-020-00362-7 |
0.327 |
|
| 2020 |
Niederkorn M, Agarwal P, Starczynowski DT. TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease. Experimental Hematology. PMID 32910997 DOI: 10.1016/J.Exphem.2020.08.010 |
0.383 |
|
| 2020 |
Muto T, Walker CS, Choi K, Hueneman K, Smith MA, Gul Z, Garcia-Manero G, Ma A, Zheng Y, Starczynowski DT. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nature Immunology. PMID 32313245 DOI: 10.1038/S41590-020-0663-Z |
0.425 |
|
| 2020 |
Jones LM, Melgar K, Bolanos L, Hueneman K, Walker MM, Jiang JK, Wilson KM, Zhang X, Shen J, Jiang F, Sutter P, Wang A, Xu X, Tawa GJ, Hoyt SB, ... ... Starczynowski DT, et al. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. The Journal of Clinical Investigation. PMID 32149729 DOI: 10.1172/Jci127907 |
0.33 |
|
| 2020 |
Niederkorn M, Hueneman K, Choi K, Varney ME, Romano L, Pujato MA, Greis KD, Inoue JI, Meetei R, Starczynowski DT. TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis. Cell Reports. 30: 2776-2790.e6. PMID 32101751 DOI: 10.1016/J.Celrep.2020.01.093 |
0.416 |
|
| 2019 |
Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, ... ... Starczynowski DT, et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 11. PMID 31484791 DOI: 10.1126/scitranslmed.aaw8828 |
0.35 |
|
| 2019 |
Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Walter M, Fraser IDC, Kulkarni A, ... ... Starczynowski DT, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology. PMID 31011167 DOI: 10.1038/S41556-019-0314-5 |
0.459 |
|
| 2019 |
Rawat R, Starczynowski DT, Ntziachristos P. Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease. Current Opinion in Cell Biology. 58: 85-94. PMID 30897496 DOI: 10.1016/J.Ceb.2019.02.008 |
0.317 |
|
| 2019 |
Chlon TM, Stepanchick E, Choi K, Zheng Y, Hueneman K, Davis A, Starczynowski DT. The Inherited MDS Gene DDX41 Is Required for Ribosome Biogenesis and Cell Viability Blood. 134: 773-773. DOI: 10.1182/Blood-2019-127471 |
0.454 |
|
| 2019 |
Barreyro L, Sampson A, Hueneman K, Choi K, Christie S, Wang D, Huang G, Starczynowski DT. Cell-Intrinsic Inflammation Drives Progression from Myelodysplastic Syndromes to Leukemia Blood. 134: 2983-2983. DOI: 10.1182/Blood-2019-127307 |
0.374 |
|
| 2019 |
Goll JB, Lindsley RC, Hooper WF, Bejar R, Walker J, Fulton R, Abel GA, Al Baghdadi T, Deeg HJ, DeZern AE, Ebert B, Epling-Burnette P, Foran JM, Gorak EJ, Gore SD, ... ... Starczynowski DT, et al. Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study Blood. 134: 4271-4271. DOI: 10.1182/Blood-2019-126978 |
0.314 |
|
| 2019 |
Choudhary GS, Smith MA, Pellagatti A, Bhagat TD, Gordon S, Pandey S, Shah N, Aluri S, Booher RN, Ramachandra M, Samson ME, Pradhan K, Bowman TV, Pillai MM, Guha C, ... ... Starczynowski DT, et al. SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML Blood. 134: 4224-4224. DOI: 10.1182/Blood-2019-124458 |
0.449 |
|
| 2019 |
Muto T, Guillamot M, Fang J, Redondo LZ, Choi K, Gong Y, Walker CS, Hueneman K, Bolanos LC, Barreyro L, Lee L, Greis KD, Khodadadi-Jamayran A, Lujambio A, Lowe SW, ... ... Starczynowski DT, et al. Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity Blood. 134: 727-727. DOI: 10.1182/Blood-2019-121423 |
0.503 |
|
| 2019 |
Bal S, Girnius S, Starczynowski D, Landau H, Choi K. Genomic Landscape of Multiple Myeloma with Elevated Lactate Dehydrogenase Biology of Blood and Marrow Transplantation. 25: S383-S384. DOI: 10.1182/Blood-2018-99-115523 |
0.348 |
|
| 2018 |
Wei Y, Zheng H, Bao N, Jiang S, Bueso-Ramos CE, Khoury J, Class C, Lu Y, Lin K, Yang H, Ganan-Gomez I, Starczynowski DT, Do KA, Colla S, Garcia-Manero G. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Advances. 2: 2491-2504. PMID 30275007 DOI: 10.1182/Bloodadvances.2018024166 |
0.402 |
|
| 2018 |
Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. PMID 30104218 DOI: 10.1182/Blood-2018-03-784116 |
0.312 |
|
| 2018 |
Fang J, Muto T, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, Sampson L, Wellendorf AM, Chetal K, Choi K, Salomonis N, Choi Y, Zheng Y, Cancelas JA, Levine RL, ... Starczynowski DT, et al. TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis. Cell Reports. 22: 1250-1262. PMID 29386112 DOI: 10.1016/J.Celrep.2018.01.013 |
0.436 |
|
| 2018 |
Barreyro L, Sampson A, Hueneman K, Bolanos LC, Pujato M, Chutipongtanate S, Wyder M, Haffey W, Choi K, Neelamraju Y, Smith MA, Niederkorn M, Ramesh V, Muto T, O'Brien E, ... ... Starczynowski DT, et al. Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies Blood. 132: 4050-4050. DOI: 10.1182/Blood-2018-99-115359 |
0.442 |
|
| 2018 |
Starczynowski DT. Chronic Innate Immune Signaling in Myelodysplasia Blood. 132: SCI-33-SCI-33. DOI: 10.1182/Blood-2018-99-109492 |
0.35 |
|
| 2017 |
Kong F, Liu Z, Jain VG, Shima K, Suzuki T, Muglia LJ, Starczynowski DT, Pasare C, Bhattacharyya S. Inhibition of IRAK1 Ubiquitination Determines Glucocorticoid Sensitivity for TLR9-Induced Inflammation in Macrophages. Journal of Immunology (Baltimore, Md. : 1950). PMID 29038250 DOI: 10.4049/Jimmunol.1700443 |
0.344 |
|
| 2017 |
Niederkorn M, Starczynowski DT. GMP-ing to Spatial Conclusions about Emergency and Leukemic Myelopoiesis. Cell Stem Cell. 20: 579-581. PMID 28475879 DOI: 10.1016/J.Stem.2017.04.005 |
0.322 |
|
| 2017 |
Smith MA, Choudhary G, Pellagatti A, Choi K, Bhagat TD, Salomonis N, Walter MJ, Komurov K, Sampson MES, Gordon S, Ahrens DV, Pradhan K, Steidl UG, Booher R, Boultwood J, ... ... Starczynowski D, et al. Splicesome Mutant MDS and AML Cells Activate Innate Immune Signaling By Regulating the Expression of Therapeutically Targetable IRAK4 Isoforms Blood. 130: 785-785. DOI: 10.1182/Blood.V130.Suppl_1.785.785 |
0.396 |
|
| 2016 |
Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch MT, ... ... Starczynowski DT, et al. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nature Immunology. PMID 28024152 DOI: 10.1038/Ni.3654 |
0.389 |
|
| 2016 |
Shimizu R, Muto T, Aoyama K, Choi K, Takeuchi M, Koide S, Hasegawa N, Isshiki Y, Togasaki E, Kawajiri-Manako C, Nagao Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, ... ... Starczynowski DT, et al. Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. Leukemia Research. 50: 85-94. PMID 27697661 DOI: 10.1016/J.Leukres.2016.09.018 |
0.387 |
|
| 2016 |
Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola M, Grimes HL, Fontanillo C, Komurov K, MacBeth K, Starczynowski DT. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nature Medicine. PMID 27294874 DOI: 10.1038/Nm.4127 |
0.359 |
|
| 2016 |
Barreyro L, Sampson AM, Bolanos L, Niederkorn M, Pujato M, Smith MA, Tomoya M, Haffey WD, Christie S, Liu X, Weirauch M, Greis K, Seibel WL, Starczynowski DT. Inhibition of UBE2N As a Therapeutic Approach in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Blood. 128: 579-579. DOI: 10.1182/Blood.V128.22.579.579 |
0.456 |
|
| 2016 |
Fang J, Bolanos L, Serrano-Lopez J, Christie S, Cancelas JA, Starczynowski DT. TRAF6 Is Essential for Maintaining Hematopoietic Stem Cell Homeostasis Blood. 128: 568-568. DOI: 10.1182/Blood.V128.22.568.568 |
0.426 |
|
| 2016 |
Melgar K, Walker M, Jiang J, Wison K, Choi K, Mulloy JC, Thomas CJ, Starczynowski DT. Molecular Analysis and In Vivo Efficacy Studies on a Novel Chemical-Series of FLT3 Inhibitors in Human FLT3-ITD AML Blood. 128: 36-36. DOI: 10.1182/Blood.V128.22.36.36 |
0.345 |
|
| 2016 |
Smith MA, Choi K, Salomonis N, Walter MJ, Komurov K, Starczynowski DT. Alternative Splice Variants of IRAK4 That Activate Innate Immune Signaling Are Associated with U2AF1 Mutations in Myelodysplastic Syndrome and Acute Myeloid Leukemia Blood. 128: 1531-1531. DOI: 10.1182/Blood.V128.22.1531.1531 |
0.426 |
|
| 2016 |
Niederkorn M, Varney M, Smith MA, Meetei RA, Starczynowski DT. Tifab, a Del(5q) MDS/AML Gene, Regulates USP15 Activity and p53 Blood. 128: 1130-1130. DOI: 10.1182/Blood.V128.22.1130.1130 |
0.448 |
|
| 2015 |
Fang J, Starczynowski DT. Genomic instability establishes dependencies on acquired gene regulatory networks: A novel role of p62 in myeloid malignancies with del(5q). Molecular & Cellular Oncology. 2: e1014219. PMID 27308507 DOI: 10.1080/23723556.2015.1014219 |
0.408 |
|
| 2015 |
Adams AK, Bolanos LC, Dexheimer PJ, Karns RA, Aronow BJ, Komurov K, Jegga AG, Casper KA, Patil YJ, Wilson KM, Starczynowski DT, Wells SI. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival. Oncotarget. PMID 26527316 DOI: 10.18632/Oncotarget.6028 |
0.401 |
|
| 2015 |
Varney ME, Niederkorn M, Konno H, Matsumura T, Gohda J, Yoshida N, Akiyama T, Christie S, Fang J, Miller D, Jerez A, Karsan A, Maciejewski JP, Meetei RA, Inoue J, ... Starczynowski DT, et al. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. The Journal of Experimental Medicine. 212: 1967-85. PMID 26458771 DOI: 10.1084/Jem.20141898 |
0.443 |
|
| 2015 |
Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, et al. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Experimental Hematology. 43: 858-868.e7. PMID 26163797 DOI: 10.1016/J.Exphem.2015.05.018 |
0.311 |
|
| 2015 |
Varney ME, Melgar K, Niederkorn M, Smith M, Barreyro L, Starczynowski DT. Deconstructing innate immune signaling in Myelodysplastic Syndromes. Experimental Hematology. PMID 26143580 DOI: 10.1016/J.Exphem.2015.05.016 |
0.374 |
|
| 2015 |
Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia. 29: 1458-69. PMID 25761935 DOI: 10.1038/Leu.2015.69 |
0.383 |
|
| 2015 |
Rhyasen GW, Starczynowski DT. IRAK signalling in cancer British Journal of Cancer. 112: 232-237. PMID 25290089 DOI: 10.1038/Bjc.2014.513 |
0.356 |
|
| 2015 |
Serrano-Lopez J, Serrano J, Zhang C, Wellendorf A, Fang J, Sanchez-Garcia J, Grimes HL, Starczynowski DT, Cancelas JA. Systemic Inflammation Recruits Ccr7+ Dendritric-Biased Granulocyte-Macrophage Progenitors to Lymphatic Circulation in a Non-Canonical Traf6-Dependent Manner Blood. 126: 785-785. DOI: 10.1182/Blood.V126.23.785.785 |
0.409 |
|
| 2015 |
Melgar K, Walker M, Jiang J, Wilson K, Mulloy JC, Thomas CJ, Starczynowski DT. Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML Blood. 126: 3690-3690. DOI: 10.1182/Blood.V126.23.3690.3690 |
0.335 |
|
| 2015 |
Fang J, Bolanos L, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Greis K, Stoilov P, Filippi M, Maciejewski JP, Garcia-Manero G, Weirauch M, Salomonis N, Geiger H, ... ... Starczynowski D, et al. Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia Blood. 126: 143-143. DOI: 10.1182/Blood.V126.23.143.143 |
0.445 |
|
| 2014 |
Chang KH, Sengupta A, Nayak RC, Duran A, Lee SJ, Pratt RG, Wellendorf AM, Hill SE, Watkins M, Gonzalez-Nieto D, Aronow BJ, Starczynowski DT, Civitelli R, Diaz-Meco MT, Moscat J, et al. p62 is required for stem cell/progenitor retention through inhibition of IKK/NF-κB/Ccl4 signaling at the bone marrow macrophage-osteoblast niche. Cell Reports. 9: 2084-97. PMID 25533346 DOI: 10.1016/J.Celrep.2014.11.031 |
0.404 |
|
| 2014 |
Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Christie S, Chen X, Rao DS, Grimes HL, Komurov K, Weirauch MT, Cancelas JA, Maciejewski JP, Starczynowski DT. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network. Cell Reports. 8: 1328-38. PMID 25199827 DOI: 10.1016/J.Celrep.2014.07.062 |
0.404 |
|
| 2014 |
Starczynowski DT. Errant innate immune signaling in del(5q) MDS. Blood. 124: 669-71. PMID 25082861 DOI: 10.1182/Blood-2014-06-581728 |
0.307 |
|
| 2014 |
Zhao JL, Starczynowski DT. Role of microRNA-146a in normal and malignant hematopoietic stem cell function. Frontiers in Genetics. 5: 219. PMID 25071842 DOI: 10.3389/Fgene.2014.00219 |
0.312 |
|
| 2014 |
Beverly LJ, Starczynowski DT. IRAK1: oncotarget in MDS and AML. Oncotarget. 5: 1699-700. PMID 24880611 DOI: 10.18632/Oncotarget.1880 |
0.473 |
|
| 2014 |
Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. An MDS xenograft model utilizing a patient-derived cell line Leukemia. 28: 1142-1145. PMID 24326684 DOI: 10.1038/Leu.2013.372 |
0.388 |
|
| 2014 |
Chang K, Sengupta A, Nayak RC, Duran A, Lee SJ, Pratt R, Wellendorf A, Hill S, Watkins M, Civitelli R, Starczynowski DT, Diaz-Meco MT, Moscat J, Cancelas JA. Sqstm1 Is Required to Retain Hematopoietic Stem Cell/ Progenitors As a Negative Regulator of Macrophage-Dependent Inflammatory Signaling in the Bone Marrow Osteoblastic Niche Blood. 124: 350-350. DOI: 10.1182/Blood.V124.21.350.350 |
0.421 |
|
| 2014 |
Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, Oliva EN, MacBeth KJ, Komurov K, Starczynowski DT. A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes Blood. 124: 1898-1898. DOI: 10.1182/Blood.V124.21.1898.1898 |
0.364 |
|
| 2013 |
Rhyasen GW, Bolanos L, Starczynowski DT. Differential IRAK signaling in hematologic malignancies. Experimental Hematology. 41: 1005-7. PMID 24084080 DOI: 10.1016/J.Exphem.2013.09.008 |
0.528 |
|
| 2013 |
Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, ... ... Starczynowski DT, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 24: 90-104. PMID 23845443 DOI: 10.1016/J.Ccr.2013.05.006 |
0.411 |
|
| 2013 |
Guo F, Zhang S, Grogg M, Cancelas JA, Varney ME, Starczynowski DT, Du W, Yang JQ, Liu W, Thomas G, Kozma S, Pang Q, Zheng Y. Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis. Haematologica. 98: 1353-8. PMID 23716557 DOI: 10.3324/Haematol.2012.080424 |
0.403 |
|
| 2013 |
Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Rao DS, Mulloy JC, Maciejewski JP, Cancelas JA, Starczynowski DT. SQSTM1/p62 Is a Necessary Cofactor In MDS/AML With Deletion Of Mir-146a Blood. 122: 747-747. DOI: 10.1182/Blood.V122.21.747.747 |
0.405 |
|
| 2013 |
Varney M, Christie S, Niederkorn M, Fang J, Jerez A, Maciejewski JP, Inoue J, Starczynowski DT. Deletion Of Tifab, a Novel Candidate Gene On Chromosome 5q, Results In Hematopoietic Defects By Changing The Dynamic Range Of Innate Immune Pathway Activation Blood. 122: 102-102. DOI: 10.1182/Blood.V122.21.102.102 |
0.404 |
|
| 2013 |
Fang J, Liu X, Barker B, Bolanos L, Wei Y, Manero GG, Starczynowski DT. Disease-Relevant Expression Of TRAF6 In Mouse HSC Results In An MDS-Like Disease Blood. 122: 101-101. DOI: 10.1182/Blood.V122.21.101.101 |
0.413 |
|
| 2012 |
Vercauteren SM, Starczynowski DT, Sung S, McNeil K, Salski C, Jensen CL, Bruyere H, Lam WL, Karsan A. T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone. British Journal of Haematology. 156: 409-12. PMID 25289412 DOI: 10.1182/Blood.V118.21.2808.2808 |
0.314 |
|
| 2012 |
Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood. 120: 858-67. PMID 22685174 DOI: 10.1182/Blood-2012-02-407999 |
0.43 |
|
| 2012 |
Fang J, Varney M, Starczynowski DT. Implication of microRNAs in the pathogenesis of MDS. Current Pharmaceutical Design. 18: 3170-9. PMID 22571695 DOI: 10.2174/1381612811209023170 |
0.305 |
|
| 2012 |
Fang J, Jerez A, Rasch C, Bolanos L, Maciejewski JP, Starczynowski DT. Haploinsufficiency of Mir-146a in High-Risk Del(5q) MDS/AML Requires an Intrachromosomal Gene Network Involving p62/TRAF6/NF-κB Blood. 120: 557-557. DOI: 10.1182/Blood.V120.21.557.557 |
0.378 |
|
| 2012 |
Ibrahim R, Woltosz JJW, Starczynowski DT, Umlandt P, Karsan A. Enforced Expression of the Toll/Interleukin-1 Receptor Associated Protein in Murine Marrow Results in MDS-Like Bone Marrow Failure Mediated by Interferon Gamma Blood. 120: 555-555. DOI: 10.1182/Blood.V120.21.555.555 |
0.354 |
|
| 2012 |
Rhyasen G, Wunderlich M, Mulloy JC, Starczynowski DT. Development and Characterization of a Novel Human Xenograft Model Using an MDS Patient-Derived Cell Line Blood. 120: 3814-3814. DOI: 10.1182/Blood.V120.21.3814.3814 |
0.398 |
|
| 2012 |
Varney M, Jerez A, Fang J, Miller D, Bolanos L, Karsan A, Maciejewski JP, Starczynowski DT. Tifab, a Novel Candidate Gene in Deletion Chromosome 5q, Contributes to Deregulation of NF-κB Signaling in MDS/AML. Blood. 120: 2812-2812. DOI: 10.1182/Blood.V120.21.2812.2812 |
0.455 |
|
| 2011 |
Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL, Karsan A. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. The Journal of Clinical Investigation. 121: 4095-105. PMID 21911935 DOI: 10.1172/Jci58818 |
0.35 |
|
| 2011 |
Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL, Humphries RK, Karsan A. MicroRNA-146a disrupts hematopoietic differentiation and survival. Experimental Hematology. 39: 167-178.e4. PMID 20933052 DOI: 10.1016/J.Exphem.2010.09.011 |
0.337 |
|
| 2011 |
Rhyasen G, Bolanos L, Fang J, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola M, Starczynowski DT. Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome Blood. 118: 612-612. DOI: 10.1182/Blood.V118.21.612.612 |
0.478 |
|
| 2011 |
Fang J, Bolanos L, Rhyasen G, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola M, Starczynowski DT. Degradation of TRAF6 by Bortezomib-Induced Autophagy Contributes to Cell Death in Acute Myeloid Leukemia and Myelodysplastic Syndrome Blood. 118: 2452-2452. DOI: 10.1182/Blood.V118.21.2452.2452 |
0.477 |
|
| 2010 |
Vercauteren SM, Sung S, Starczynowski DT, Lam WL, Bruyere H, Horsman DE, Tsang P, Leitch H, Karsan A. Array comparative genomic hybridization of peripheral blood granulocytes of patients with myelodysplastic syndrome detects karyotypic abnormalities. American Journal of Clinical Pathology. 134: 119-26. PMID 20551276 DOI: 10.1309/Ajcph27Zizejlorf |
0.307 |
|
| 2010 |
Starczynowski DT, Karsan A. Innate immune signaling in the myelodysplastic syndromes. Hematology/Oncology Clinics of North America. 24: 343-59. PMID 20359630 DOI: 10.1016/J.Hoc.2010.02.008 |
0.335 |
|
| 2010 |
Starczynowski DT, Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle (Georgetown, Tex.). 9: 855-6. PMID 20160505 DOI: 10.4161/Cc.9.5.11156 |
0.302 |
|
| 2010 |
Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature Medicine. 16: 49-58. PMID 19898489 DOI: 10.1038/Nm.2054 |
0.346 |
|
| 2008 |
Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, Spinelli JJ, Eaves CJ, Eaves AC, Horsman DE, Lam WL, Karsan A. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood. 112: 3412-24. PMID 18663149 DOI: 10.1182/Blood-2007-11-122028 |
0.317 |
|
| 2008 |
Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi AL, Hirst M, Hogge DE, Marra M, Wells RA, Lam W, Humphries RK, Karsan A. Identification of Mir-145 and Mir-146a as Micrornas Involved in the Pathogenesis of 5q- Syndrome Blood. 112: 853-853. DOI: 10.1182/Blood.V112.11.853.853 |
0.328 |
|
| 2007 |
Starczynowski DT, Trautmann H, Pott C, Harder L, Arnold N, Africa JA, Leeman JR, Siebert R, Gilmore TD. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity. Oncogene. 26: 2685-94. PMID 17072339 DOI: 10.1038/Sj.Onc.1210089 |
0.77 |
|
| 2007 |
Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, Spinelli JJ, Eaves CJ, Eaves AC, Horsman DE, Lam WL, Karsan A. High-Resolution CGH Analysis of CD34+ Cells from Lower-Risk Myelodysplastic Patients Reveals Cryptic Copy Number Alterations and Predicts Overall and Leukemia-Free Survival. Blood. 110: 2431-2431. DOI: 10.1182/Blood.V110.11.2431.2431 |
0.343 |
|
| 2005 |
Starczynowski DT, Reynolds JG, Gilmore TD. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene. 24: 7355-68. PMID 16027730 DOI: 10.1038/Sj.Onc.1208902 |
0.642 |
|
| 2005 |
Trautmann H, Starczynowski DT, Pott C, Harder L, Arnold N, Siebert R, Kneba M, Gilmore TD. An Activating Mutation (Ser525Pro) within the Transactivation Domain of REL in Two Patients with Human B-Cell Lymphomas Enhances REL’s In Vitro Transforming Activity. Blood. 106: 2617-2617. DOI: 10.1182/Blood.V106.11.2617.2617 |
0.688 |
|
| 2004 |
Kalaitzidis D, Ok J, Sulak L, Starczynowski DT, Gilmore TD. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene. 23: 7580-7. PMID 15326488 DOI: 10.1038/Sj.Onc.1207912 |
0.74 |
|
| 2004 |
Gilmore TD, Starczynowski DT, Kalaitzidis D. RELevant gene amplification in B-cell lymphomas? Blood. 103: 3243-4; author reply. PMID 15070712 DOI: 10.1182/Blood-2003-11-4019 |
0.758 |
|
| 2004 |
Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 23: 2275-86. PMID 14755244 DOI: 10.1038/Sj.Onc.1207410 |
0.757 |
|
| 2003 |
Starczynowski DT, Reynolds JG, Gilmore TD. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene. 22: 6928-36. PMID 14534540 DOI: 10.1038/Sj.Onc.1206801 |
0.65 |
|
| 2002 |
Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Letters. 181: 1-9. PMID 12430173 DOI: 10.1016/S0304-3835(01)00795-9 |
0.756 |
|
| Show low-probability matches. |